BridgeBio Pharma (BBIO) Non-Current Debt (2018 - 2026)

BridgeBio Pharma has reported Non-Current Debt for 9 years, with the latest figure at $2.7 billion in Q1 2026.

• Quarterly Non-Current Debt changed N/A year-over-year to $2.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (changed N/A YoY) and the FY2025 annual result came in at $740.9 million, up 69.41% from the prior year.
• Non-Current Debt advanced to $2.7 billion in Q1 2026 per BBIO's latest filing, from $740.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $2.7 billion in Q1 2026 and troughed at $418.4 million in Q2 2022.
• A 5-year average of $707.7 million and a median of $436.2 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt jumped 378.3% in 2022, then fell 2.04% in 2024.
• Over 5 years, Non-Current Debt stood at $431.0 million in 2022, then climbed by 3.59% to $446.4 million in 2023, then dropped by 2.04% to $437.3 million in 2024, then surged by 69.41% to $740.9 million in 2025, then soared by 258.07% to $2.7 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $2.7 billion, $740.9 million, and $2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.